I
Interface Biologics
Interface Biologics develops transformative biomedical polymer technology to improve the safety and effectiveness of medical devices
About Interface Biologics
Interface Biologics, Inc. is a commercial-stage company specializing in the development of advanced biomedical polymer technologies. These technologies are designed to improve the safety and effectiveness of medical devices and the targeted delivery of drugs. The company's core products include surface modification additives that are clinically proven to reduce infection and thrombus-related complications in FDA-cleared medical devices. Additionally, Interface Biologics offers sustained local drug delivery technologies applicable across various drug classes and medical specialties, with an initial focus on ophthalmology. The company primarily serves medical device manufacturers and pharmaceutical companies operating in the medtech and pharma markets. Interface Biologics generates revenue through the sale of its innovative materials and technologies, which are integrated into medical devices and drug delivery systems. The company’s team comprises chemists, engineers, and material scientists with extensive experience in managing industry growth.
Source: Dealroom company dataAt a glance
- Founded
- 2001
- Headquarters
- Toronto, Canada
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Interface Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Interface Biologics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.


